On the public citation graph

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

https://doi.org/10.1056/nejmoa2030183
0 signed · 1909 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2010.1322openalex-snapshot
Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
inferredcites →https://doi.org/10.1001/jama.295.2.180openalex-snapshot
International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
inferredcites →https://doi.org/10.1001/jama.297.11.1197openalex-snapshot
One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis
inferredcites →https://doi.org/10.1001/jamacardio.2016.3030openalex-snapshot
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk
inferredcites →https://doi.org/10.1002/ejhf.1713openalex-snapshot
Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)
inferredcites →https://doi.org/10.1002/sim.4780131709openalex-snapshot
Standardized rates of recurrent outcomes
inferredcites →https://doi.org/10.1007/s10985-019-09462-4openalex-snapshot
Modeling marginal features in studies of recurrent events in the presence of a terminal event
inferredcites →https://doi.org/10.1016/j.bbrc.2020.01.015openalex-snapshot
The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension
inferredcites →https://doi.org/10.1016/j.cmet.2018.11.010openalex-snapshot
Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?
inferredcites →https://doi.org/10.1016/j.cmet.2019.08.015openalex-snapshot
SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1016/j.cmet.2019.10.008openalex-snapshot
The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure
inferredcites →https://doi.org/10.1016/j.jacbts.2018.01.010openalex-snapshot
Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia
inferredcites →https://doi.org/10.1016/j.jacc.2015.11.027openalex-snapshot
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding
inferredcites →https://doi.org/10.1016/j.jacc.2018.08.2202openalex-snapshot
Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling
inferredcites →https://doi.org/10.1016/j.jacc.2020.05.041openalex-snapshot
The Consequences of the COVID-19 Pandemic on Non-COVID-19 Clinical Trials
inferredcites →https://doi.org/10.1016/j.jacc.2020.07.051openalex-snapshot
Effects of the COVID-19 Pandemic on Active Non-COVID Clinical Trials
inferredcites →https://doi.org/10.1016/j.jvs.2010.12.013openalex-snapshot
Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
inferredcites →https://doi.org/10.1016/s0140-6736(18)32590-xopenalex-snapshot
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
inferredcites →https://doi.org/10.1016/s0735-1097(00)00531-3openalex-snapshot
Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure
inferredcites →https://doi.org/10.1016/s2213-8587(15)00044-3openalex-snapshot
Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
inferredcites →https://doi.org/10.1038/s41569-020-00439-7openalex-snapshot
The COVID-19 pandemic: a catalyst to improve clinical trials
inferredcites →https://doi.org/10.1056/nejmoa1007964openalex-snapshot
Clopidogrel with or without Omeprazole in Coronary Artery Disease
inferredcites →https://doi.org/10.1056/nejmoa1307684openalex-snapshot
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1056/nejmoa1504720openalex-snapshot
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1611925openalex-snapshot
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1708337openalex-snapshot
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1811744openalex-snapshot
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
inferredcites →https://doi.org/10.1056/nejmoa1812389openalex-snapshot
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1911303openalex-snapshot
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
inferredcites →https://doi.org/10.1056/nejmoa2004967openalex-snapshot
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa2022190openalex-snapshot
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
inferredcites →https://doi.org/10.1056/nejmoa2024816openalex-snapshot
Dapagliflozin in Patients with Chronic Kidney Disease
inferredcites →https://doi.org/10.1080/01621459.1989.10478874openalex-snapshot
The Robust Inference for the Cox Proportional Hazards Model
inferredcites →https://doi.org/10.1093/ndt/gfz294openalex-snapshot
The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial
inferredcites →https://doi.org/10.1111/dom.14127openalex-snapshot
Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2
inferredcites →https://doi.org/10.1139/cjpp-2018-0359openalex-snapshot
Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications
inferredcites →https://doi.org/10.1161/circheartfailure.119.006720openalex-snapshot
Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials
inferredcites →https://doi.org/10.1161/circulationaha.114.010389openalex-snapshot
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
inferredcites →https://doi.org/10.1161/circulationaha.114.014796openalex-snapshot
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death
inferredcites →https://doi.org/10.1161/circulationaha.119.040130openalex-snapshot
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1161/circulationaha.119.041181openalex-snapshot
More CREDENCE for SGLT2 Inhibition
inferredcites →https://doi.org/10.1161/circulationaha.119.042375openalex-snapshot
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
inferredcites →https://doi.org/10.1161/jaha.120.018274openalex-snapshot
The Landscape of Cardiovascular Clinical Trials in the United States Initiated Before and During COVID‐19
inferredcites →https://doi.org/10.1210/clinem/dgz258openalex-snapshot
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
inferredcites →https://doi.org/10.2337/dc14-1850openalex-snapshot
Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial
inferredcites →https://doi.org/10.2337/dc14-2806openalex-snapshot
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
inferredcites →https://doi.org/10.2337/dc18-0342openalex-snapshot
HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study
inferredcites →https://doi.org/10.2337/dc18-0343openalex-snapshot
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
inferredcites →https://doi.org/10.2337/dc18-1959openalex-snapshot
Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
inferredcites →https://doi.org/10.2337/dc19-1410openalex-snapshot
Reinterpreting Cardiorenal Protection of Renal Sodium–Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming
inferredcites →https://doi.org/10.2337/dci19-0074openalex-snapshot
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.5116096openalex-extracted
Outcome Measures for Randomised Clinical Trials and Multicentre Observational Studies of Cardiovascular Diseases Published in Major Clinical Journals: Systematic Review and Evidence Mapping
inferred← citeshttps://doi.org/10.1001/jama.2024.27402openalex-snapshot
Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes
inferred← citeshttps://doi.org/10.1001/jama.2025.20835openalex-snapshot
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria
inferred← citeshttps://doi.org/10.1001/jamacardio.2020.7596openalex-snapshot
Expediting the Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure—There Is No Time for Delay
inferred← citeshttps://doi.org/10.1001/jamacardio.2021.0496openalex-snapshot
Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed
inferred← citeshttps://doi.org/10.1001/jamacardio.2022.2847openalex-snapshot
Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction
inferred← citeshttps://doi.org/10.1001/jamacardio.2023.4664openalex-snapshot
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.14501openalex-snapshot
Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.35152openalex-snapshot
A Natural Language Processing–Based Approach for Identifying Hospitalizations for Worsening Heart Failure Within an Integrated Health Care Delivery System
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.42078openalex-snapshot
Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.43201openalex-snapshot
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.30754openalex-snapshot
Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.46684openalex-snapshot
Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.5135openalex-snapshot
SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart Failure
inferred← citeshttps://doi.org/10.1002/14651858.cd013650.pub2openalex-snapshot
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
inferred← citeshttps://doi.org/10.1002/14651858.cd015588.pub2openalex-snapshot
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
inferred← citeshttps://doi.org/10.1002/9781119697473.ch37openalex-snapshot
How to Use Type 2 Diabetes Treatments in Clinical Practice
inferred← citeshttps://doi.org/10.1002/9781119697473.ch50openalex-snapshot
Heart Failure and Diabetes
inferred← citeshttps://doi.org/10.1002/9781119785033.ch5openalex-snapshot
SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1002/bcp.70187openalex-snapshot
Cost–utility analysis of sotagliflozin for heart failure patients with diabetes in China
inferred← citeshttps://doi.org/10.1002/bcp.70823openalex-snapshot
Effect of dapagliflozin on electrocardiographic arrhythmic markers in patients with type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1002/ccd.70852openalex-snapshot
Clinical Outcomes of Sodium Glucose Cotransporter‐2 Inhibitors in Patients Undergoing Mitral Transcatheter Edge‐to‐Edge Repair
inferred← citeshttps://doi.org/10.1002/cdt3.59openalex-snapshot
Pharmacotherapy treatment patterns at hospital discharge and clinical outcomes among patients with heart failure with reduced ejection fraction
inferred← citeshttps://doi.org/10.1002/clc.23845openalex-snapshot
Improving implementation of evidence‐based therapies for heart failure
inferred← citeshttps://doi.org/10.1002/clc.23846openalex-snapshot
Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
inferred← citeshttps://doi.org/10.1002/clc.23849openalex-snapshot
Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction
inferred← citeshttps://doi.org/10.1002/clc.24104openalex-snapshot
Development and validation of a prediction model based on machine learning algorithms for predicting the risk of heart failure in middle‐aged and older US people with prediabetes or diabetes
inferred← citeshttps://doi.org/10.1002/ctd2.70204openalex-snapshot
SGLT2i in heart failure: Cardiorenal mechanisms, clinical evidence and translational perspectives
inferred← citeshttps://doi.org/10.1002/ddr.70187openalex-snapshot
Emerging in Diabetic Cardiomyopathy: Molecular Pathways and Targets for Therapeutic Intervention
inferred← citeshttps://doi.org/10.1002/dmrr.3755openalex-snapshot
Cardio‐renal‐metabolic disease in primary care setting
inferred← citeshttps://doi.org/10.1002/edm2.303openalex-snapshot
Benefits and harms of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2‐I) and renin–angiotensin–aldosterone system inhibitors (RAAS‐I) versus SGLT2‐Is alone in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1002/ehf2.13124openalex-snapshot
Heart Failure in the Last Year: Progress and Perspective
inferred← citeshttps://doi.org/10.1002/ehf2.13148openalex-snapshot
Early Initiation of SGLT2 Inhibitors is Important, Irrespective of Ejection Fraction: SOLOIST-WHF in Perspective
inferred← citeshttps://doi.org/10.1002/ehf2.13169openalex-snapshot
Efficacy and Safety of SGLT2 Inhibitors in Heart Failure: Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1002/ehf2.13313openalex-snapshot
SGLT2i Versus ARNI in Heart Failure with Reduced Ejection Fraction: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1002/ehf2.13380openalex-snapshot
Eligibility of Outpatients with Chronic Heart Failure for Sodium–Glucose Co-Transporter-2 Inhibitors
inferred← citeshttps://doi.org/10.1002/ehf2.13406openalex-snapshot
Design and Rationale of the EMPA-VISION Trial: Investigating the Metabolic Effects of Empagliflozin in Patients with Heart Failure
inferred← citeshttps://doi.org/10.1002/ehf2.13452openalex-snapshot
Sodium–Glucose Cotransporter 2 Inhibitor-Induced Euglycaemic Diabetic Ketoacidosis in Heart Failure with Preserved Ejection Fraction
inferred← citeshttps://doi.org/10.1002/ehf2.13472openalex-snapshot
Prospective Association of Serum Adipocyte Fatty Acid-Binding Protein with Heart Failure Hospitalization in Diabetes
inferred← citeshttps://doi.org/10.1002/ehf2.13483openalex-snapshot
Sodium-Glucose Cotransporter 2 Inhibitor Effects on Heart Failure Hospitalization and Cardiac Function: Systematic Review
inferred← citeshttps://doi.org/10.1002/ehf2.13553openalex-snapshot
Acute Pleiotropic Effects of Dapagliflozin in Type 2 Diabetic Patients with Heart Failure with Reduced Ejection Fraction: A Crossover Trial
inferred← citeshttps://doi.org/10.1002/ehf2.13615openalex-snapshot
Mediators of the Improvement in Heart Failure Outcomes with Empagliflozin in the EMPA-REG OUTCOME Trial
inferred← citeshttps://doi.org/10.1002/ehf2.13646openalex-snapshot
‘Time is Prognosis’ in Heart Failure: Time-to-Treatment Initiation as a Modifiable Risk Factor
inferred← citeshttps://doi.org/10.1002/ehf2.13760openalex-snapshot
A Year in Heart Failure: An Update of Recent Findings
inferred← citeshttps://doi.org/10.1002/ehf2.13785openalex-snapshot
Robustness of Outcomes in Trials Evaluating Sodium–Glucose Co-Transporter 2 Inhibitors for Heart Failure
inferred← citeshttps://doi.org/10.1002/ehf2.13805openalex-snapshot
Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Reduced or Preserved Ejection Fraction: A Meta-Analysis
inferred← citeshttps://doi.org/10.1002/ehf2.13841openalex-snapshot
Genetic Variation in Sodium Glucose Co-Transporter 1 and Cardiac Structure and Function at Middle Age
inferred← citeshttps://doi.org/10.1002/ehf2.13905openalex-snapshot
Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: An Updated Meta-Analysis
inferred← citeshttps://doi.org/10.1002/ehf2.13910openalex-snapshot
Cardiovascular Outcomes Associated with Treatment of Type 2 Diabetes in Patients with Ischaemic Heart Failure
inferred← citeshttps://doi.org/10.1002/ehf2.14005openalex-snapshot
Promise of Sodium–Glucose Co-Transporter-2 Inhibitors in Heart Failure with Mildly Reduced Ejection Fraction
inferred← citeshttps://doi.org/10.1002/ehf2.14024openalex-snapshot
A Survey-Based Triage Tool to Identify Patients Potentially Eligible for Referral to an Advanced Heart Failure Centre
inferred← citeshttps://doi.org/10.1002/ehf2.14090openalex-snapshot
Use of Sodium Glucose Co-Transporter 2 Inhibitors in Acute Heart Failure: A Practical Guidance
inferred← citeshttps://doi.org/10.1002/ehf2.14095openalex-snapshot
Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Chronic Kidney Disease
inferred← citeshttps://doi.org/10.1002/ehf2.14224openalex-snapshot
Diabetic Cardiomyopathy: A Brief Summary on Lipid Toxicity
inferred← citeshttps://doi.org/10.1002/ehf2.14248openalex-snapshot
Are Arrhythmias the Drivers of Sudden Cardiac Death in Heart Failure with Preserved Ejection Fraction? A Review
inferred← citeshttps://doi.org/10.1002/ehf2.14297openalex-snapshot
Indirect Comparison of SGLT2 Inhibitors in Patients with Established Heart Failure: Evidence Based on Bayesian Methods
inferred← citeshttps://doi.org/10.1002/ehf2.14354openalex-snapshot
Regional Management of Worsening Heart Failure: Rationale and Design of the CHAIN-HF Registry
inferred← citeshttps://doi.org/10.1002/ehf2.14355openalex-snapshot
Systematic Review of Sodium-Glucose Cotransporter 2 Inhibitors: A Hopeful Prospect in Tackling Heart Failure-Related Events
inferred← citeshttps://doi.org/10.1002/ehf2.14633openalex-snapshot
Safety of Sodium-Glucose Cotransporter 2 Inhibitors Drugs Among Heart Failure Patients: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1002/ehf2.14638openalex-snapshot
Medicines Optimization Prior to Discharge in Patients Admitted to Hospital with Heart Failure
inferred← citeshttps://doi.org/10.1002/ehf2.14647openalex-snapshot
Role of Vericiguat in Management of Patients with Heart Failure with Reduced Ejection Fraction After Worsening Episode
inferred← citeshttps://doi.org/10.1002/ehf2.14687openalex-snapshot
Heart Failure Care in the Central and Eastern Europe and Baltic Region: Status, Barriers, and Routes to Improvement
inferred← citeshttps://doi.org/10.1002/ehf2.14726openalex-snapshot
Comparison of Cardiovascular Outcomes of New Antihyperglycemic Agents in Type 2 Diabetes Mellitus: A Meta-Analysis
inferred← citeshttps://doi.org/10.1002/ehf2.14979openalex-snapshot
Effect of Sex on Sodium-Glucose Co-Transporter-2 Antagonists and Glucagon-Like Peptide-1 Agonists in Heart Failure
inferred← citeshttps://doi.org/10.1002/ehf2.15036openalex-snapshot
Meta-Analysis of Sotagliflozin, a Dual Sodium-Glucose-Cotransporter 1/2 Inhibitor, for Heart Failure in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1002/ehf2.15088openalex-snapshot
Long-Term Efficacy of SGLT2 Inhibitors for Elderly Patients with Acute Decompensated Heart Failure: The OASIS-HF Study
inferred← citeshttps://doi.org/10.1002/ehf2.15136openalex-snapshot
Effects of Sodium–Glucose Co-Transporter Inhibitors on Individual Clinical Endpoints and Quality of Life
inferred← citeshttps://doi.org/10.1002/ehf2.15286openalex-snapshot
Early Prescription of Quadruple Therapy in Acute Decompensated Heart Failure with Reduced Ejection Fraction: A Propensity Score-Matched Analysis
inferred← citeshttps://doi.org/10.1002/ehf2.15293openalex-snapshot
Early Administration of SGLT2 Inhibitors in Hospitalized Patients: A Practical Guidance from the Current Evidence
inferred← citeshttps://doi.org/10.1002/ehf2.15386openalex-snapshot
Initial Clinical Experience with Dapagliflozin in Addition to Optimized Medical Therapy in Paediatric Heart Failure Patients
inferred← citeshttps://doi.org/10.1002/ehf2.15408openalex-snapshot
SGLT2 Inhibitors for the Prevention and Treatment of Heart Failure: A Scientific Statement of the HFA and the HFAI
inferred← citeshttps://doi.org/10.1002/ejhf.2065openalex-snapshot
Design of a Prospective Patient-Level Pooled Analysis of Two Parallel Trials of Empagliflozin in Patients with Established Heart Failure
inferred← citeshttps://doi.org/10.1002/ejhf.2070openalex-snapshot
Discovery and Care Innovation Amidst a Pandemic
inferred← citeshttps://doi.org/10.1002/ejhf.2075openalex-snapshot
SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
inferred← citeshttps://doi.org/10.1002/ejhf.2108openalex-snapshot
Sodium–glucose co‐transporter 2 inhibitors—the first successful treatment for heart failure with preserved ejection fraction?
inferred← citeshttps://doi.org/10.1002/ejhf.2116openalex-snapshot
Acute heart failure treatment: a light at the end of the tunnel?
inferred← citeshttps://doi.org/10.1002/ejhf.2131openalex-snapshot
Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
inferred← citeshttps://doi.org/10.1002/ejhf.2135openalex-snapshot
Prevention of heart failure events with sodium–glucose co‐transporter 2 inhibitors across a spectrum of cardio‐renal‐metabolic risk
inferred← citeshttps://doi.org/10.1002/ejhf.2137openalex-snapshot
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial
inferred← citeshttps://doi.org/10.1002/ejhf.2149openalex-snapshot
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction
inferred← citeshttps://doi.org/10.1002/ejhf.2170openalex-snapshot
Sodium–glucose co‐transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness
inferred← citeshttps://doi.org/10.1002/ejhf.2172openalex-snapshot
Sodium–glucose co‐transporter 2 inhibitors: strength of evidence for a cardio‐renal‐metabolic therapy
inferred← citeshttps://doi.org/10.1002/ejhf.2206openalex-snapshot
Patient Profiling in Heart Failure for Tailoring Medical Therapy. A Consensus Document of the Heart Failure Association of the European Society of Cardiology
inferred← citeshttps://doi.org/10.1002/ejhf.2214openalex-snapshot
Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratian principle ‘do no harm’?
inferred← citeshttps://doi.org/10.1002/ejhf.2249openalex-snapshot
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
inferred← citeshttps://doi.org/10.1002/ejhf.2279openalex-snapshot
Sodium–glucose co‐transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism
inferred← citeshttps://doi.org/10.1002/ejhf.2286openalex-snapshot
Cardiac, Renal, and Metabolic Effects of Sodium–Glucose Co-Transporter 2 Inhibitors: A Position Paper from the European Society of Cardiology Ad-Hoc Task Force on Sodium–Glucose Co-Transporter 2 Inhibitors
inferred← citeshttps://doi.org/10.1002/ejhf.2333openalex-snapshot
2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
inferred← citeshttps://doi.org/10.1002/ejhf.2336openalex-snapshot
The sodium–glucose co‐transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox
inferred← citeshttps://doi.org/10.1002/ejhf.2358openalex-snapshot
Effects of an outpatient intervention comprising nurse‐led non‐invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure ( AMULET study): a randomised controlled trial
inferred← citeshttps://doi.org/10.1002/ejhf.2378openalex-snapshot
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction
inferred← citeshttps://doi.org/10.1002/ejhf.2397openalex-snapshot
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
inferred← citeshttps://doi.org/10.1002/ejhf.2399openalex-snapshot
Ejection fraction in heart failure: just become Emperor's new clothes?
inferred← citeshttps://doi.org/10.1002/ejhf.2433openalex-snapshot
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
inferred← citeshttps://doi.org/10.1002/ejhf.2441openalex-snapshot
A promise unfulfilled: the use of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction
inferred← citeshttps://doi.org/10.1002/ejhf.2503openalex-snapshot
Practical outpatient management of worsening chronic heart failure
inferred← citeshttps://doi.org/10.1002/ejhf.2508openalex-snapshot
Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT‐HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure)
inferred← citeshttps://doi.org/10.1002/ejhf.2509openalex-snapshot
What's all the fuss about a new guideline?
inferred← citeshttps://doi.org/10.1002/ejhf.2542openalex-snapshot
Head‐to‐head comparison between recommendations by the ESC and ACC / AHA / HFSA heart failure guidelines
inferred← citeshttps://doi.org/10.1002/ejhf.2560openalex-snapshot
Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction ( DAPA‐VO 2 ): a randomized clinical trial
inferred← citeshttps://doi.org/10.1002/ejhf.2576openalex-snapshot
Left ventricular ejection fraction as the primary heart failure phenotyping parameter
inferred← citeshttps://doi.org/10.1002/ejhf.2584openalex-snapshot
Side effects and treatment initiation barriers of sodium–glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/ejhf.2633openalex-snapshot
Tolerability and safety barriers to sodium–glucose cotransporter 2 inhibitor initiation in heart failure with reduced ejection fraction
inferred← citeshttps://doi.org/10.1002/ejhf.2678openalex-snapshot
Diagnosing heart failure with preserved ejection fraction in cardiac amyloidosis or diagnosing cardiac amyloidosis in heart failure with preserved ejection fraction?
inferred← citeshttps://doi.org/10.1002/ejhf.2711openalex-snapshot
Inhibiting the proximal nephron in acute heart failure – emerging data on kidney safety and efficacy
inferred← citeshttps://doi.org/10.1002/ejhf.2720openalex-snapshot
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum
inferred← citeshttps://doi.org/10.1002/ejhf.2738openalex-snapshot
Health‐related quality of life outcomes in PARAGON‐HF
inferred← citeshttps://doi.org/10.1002/ejhf.2754openalex-snapshot
Targeting the ‘Vulnerable’ Period – First 3–6 Months After an Acute Heart Failure Admission – the Light Gets Brighter
inferred← citeshttps://doi.org/10.1002/ejhf.2766openalex-snapshot
Little at a Time: Trying to Understand the Battery of Benefits of Sodium–Glucose Contransporter 2 Inhibitors in Heart Failure
inferred← citeshttps://doi.org/10.1002/ejhf.2773openalex-snapshot
Acute Heart Failure After Non-Cardiac Surgery: Incidence, Phenotypes, Determinants and Outcomes
inferred← citeshttps://doi.org/10.1002/ejhf.2777openalex-snapshot
Cost-Effectiveness of Immediate Initiation of Dapagliflozin in Patients with a History of Heart Failure
inferred← citeshttps://doi.org/10.1002/ejhf.2778openalex-snapshot
Use of Patient-Reported Outcomes in Heart Failure: From Clinical Trials to Routine Practice
inferred← citeshttps://doi.org/10.1002/ejhf.2825openalex-snapshot
Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors and Angiotensin Receptor–Neprilysin Inhibitors for Heart Failure in Black Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.1002/ejhf.2864openalex-snapshot
Potential Global Impact of Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure
inferred← citeshttps://doi.org/10.1002/ejhf.2874openalex-snapshot
Worsening of Chronic Heart Failure: Definition, Epidemiology, Management and Prevention. A Clinical Consensus Statement by the Heart Failure Association of the European Society of Cardiology
inferred← citeshttps://doi.org/10.1002/ejhf.2894openalex-snapshot
Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
inferred← citeshttps://doi.org/10.1002/ejhf.2915openalex-snapshot
Renal and Blood Pressure Effects of Dapagliflozin in Recently Hospitalized Patients with Heart Failure with mildly reduced or Preserved Ejection Fraction: Insights from the DELIVER Trial
inferred← citeshttps://doi.org/10.1002/ejhf.2916openalex-snapshot
Acute Heart Failure is a Remitting–Relapsing Disorder and not a Step Towards Advanced Heart Failure: Implications for Decongestion Therapy
inferred← citeshttps://doi.org/10.1002/ejhf.2920openalex-snapshot
Safety, Tolerability and Efficacy of Up-Titration of Guideline-Directed Medical Therapies for Acute Heart Failure in Elderly Patients: A Sub-Analysis of the STRONG-HF Randomized Clinical Trial
inferred← citeshttps://doi.org/10.1002/ejhf.2971openalex-snapshot
Real-World Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry
inferred← citeshttps://doi.org/10.1002/ejhf.2990openalex-snapshot
Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial
inferred← citeshttps://doi.org/10.1002/ejhf.3024openalex-snapshot
2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
inferred← citeshttps://doi.org/10.1002/ejhf.3087openalex-snapshot
Rationale and Design of the ESC Heart Failure III Registry – Implementation and Discovery
inferred← citeshttps://doi.org/10.1002/ejhf.3109openalex-snapshot
Effective Medications can Work Only in Patients Who Take Them: Implications for Post-Acute Heart Failure Care
inferred← citeshttps://doi.org/10.1002/ejhf.3174openalex-snapshot
Blood Pressure and Intensive Treatment Up-Titration After Acute Heart Failure Hospitalization: Insights from the STRONG-HF Trial
inferred← citeshttps://doi.org/10.1002/ejhf.3218openalex-snapshot
Treatment Effects of Empagliflozin in Hospitalized Heart Failure Patients Across the Range of Left Ventricular Ejection Fraction – Results from the EMPULSE Trial
inferred← citeshttps://doi.org/10.1002/ejhf.3240openalex-snapshot
Time to Clinical Benefit with Sotagliflozin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Insights from the SCORED Randomized Trial
inferred← citeshttps://doi.org/10.1002/ejhf.3256openalex-snapshot
Follow the EMPULSE: In-Hospital Initiation of Empagliflozin for Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction
inferred← citeshttps://doi.org/10.1002/ejhf.3292openalex-snapshot
Effects of Canagliflozin on Total Heart Failure Events Across the Kidney Function Spectrum: Participant-Level Pooled Analysis from the CANVAS Program and CREDENCE Trial
inferred← citeshttps://doi.org/10.1002/ejhf.3416openalex-snapshot
Differences in Heart Failure with Preserved Ejection Fraction Management Between Care Providers: An International Survey
inferred← citeshttps://doi.org/10.1002/ejhf.3440openalex-snapshot
Quality of Life in Heart Failure. The Heart of the Matter. A Scientific Statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology
inferred← citeshttps://doi.org/10.1002/ejhf.3444openalex-snapshot
Translating the 2021 ESC Heart Failure Guideline Recommendations in Daily Practice: Results from a Heart Failure Survey. A Scientific Statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC
inferred← citeshttps://doi.org/10.1002/ejhf.3453openalex-snapshot
The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and Design
inferred← citeshttps://doi.org/10.1002/ejhf.3464openalex-snapshot
Timing of Sodium–Glucose Cotransporter 2 Inhibitor Initiation and Post-Discharge Outcomes in Acute Heart Failure with Diabetes: A Population-Based Cohort Study
inferred← citeshttps://doi.org/10.1002/ejhf.3558openalex-snapshot
Tailoring Medical Therapy for Heart Failure with Preserved Ejection Fraction
inferred← citeshttps://doi.org/10.1002/ejhf.3618openalex-snapshot
Clinical Management and Therapeutic Optimization of Patients with Heart Failure with Reduced Ejection Fraction and Low Blood Pressure. A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC
inferred← citeshttps://doi.org/10.1002/ejhf.3626openalex-snapshot
Low Blood Pressure and the Effect of Empagliflozin in Acute Heart Failure: An EMPULSE Analysis
inferred← citeshttps://doi.org/10.1002/ejhf.3646openalex-snapshot
The Use of Left Ventricular Ejection Fraction in the Diagnosis and Management of Heart Failure. A Clinical Consensus Statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS)
inferred← citeshttps://doi.org/10.1002/ejhf.70094openalex-snapshot
Combination Diuretic Therapy in Acute Heart Failure: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1002/jac5.1871openalex-snapshot
Part I: PSAP Live : Updates from 2022 Book 1 ( Cardiology )
inferred← citeshttps://doi.org/10.1002/jimd.12752openalex-snapshot
Repurposing SGLT2 inhibitors: Treatment of renal proximal tubulopathy in Fanconi‐Bickel syndrome with empagliflozin
inferred← citeshttps://doi.org/10.1002/mdc3.13893openalex-snapshot
Meta‐analysis of Association between Newer Glucose‐Lowering Drugs and Risk of Parkinson's Disease
inferred← citeshttps://doi.org/10.1002/phar.2527openalex-snapshot
Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction
inferred← citeshttps://doi.org/10.1002/phar.2839openalex-snapshot
Expanded use of sodium‐glucose cotransporter 2 inhibitors: Evidence beyond heart failure with reduced ejection fraction
inferred← citeshttps://doi.org/10.1002/psb.2014openalex-snapshot
Emerging roles of sodium‐glucose co‐transporter inhibitors
inferred← citeshttps://doi.org/10.1007/164_2021_537openalex-snapshot
Glycaemic Control in Diabetes
inferred← citeshttps://doi.org/10.1007/164_2021_576openalex-snapshot
Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities
inferred← citeshttps://doi.org/10.1007/164_2026_826openalex-snapshot
Safety and Tolerability of SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1007/164_2026_827openalex-snapshot
Clinical Evidence of Cardioprotective Effects of SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1007/164_2026_847openalex-snapshot
Clinical Evidence of Kidney Protection Exerted by SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1007/164_2026_853openalex-snapshot
SGLT2 Inhibitors as Potential Agents for Prevention, Treatment, and/or Improved Recovery from Acute Kidney Injury
inferred← citeshttps://doi.org/10.1007/978-1-4939-0779-3_192-2openalex-snapshot
Heart Failure
inferred← citeshttps://doi.org/10.1007/978-3-031-13009-0_20openalex-snapshot
New Antidiabetic Agents: Relevance to Cardiovascular Outcomes
inferred← citeshttps://doi.org/10.1007/978-3-031-13009-0_28openalex-snapshot
Control of Blood Glucose and Cardiovascular Risk Profile
inferred← citeshttps://doi.org/10.1007/978-3-031-13177-6_27openalex-snapshot
Heart Failure and Cardiac Dysfunction in Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-031-13177-6_37openalex-snapshot
Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual
inferred← citeshttps://doi.org/10.1007/978-3-031-44648-1_21openalex-snapshot
Glycemic Management in Coronary Artery Bypass Graft Patients
inferred← citeshttps://doi.org/10.1007/978-3-031-44648-1_6openalex-snapshot
Use of Non-insulin Agents for Hyperglycemia Management in Hospitalized Patients
inferred← citeshttps://doi.org/10.1007/978-3-032-12626-9_15openalex-snapshot
Guideline Directed Medical Therapy and How to Get There
inferred← citeshttps://doi.org/10.1007/978-3-032-12626-9_8openalex-snapshot
Sodium Glucose Transport Protein-2 (SGLT-2) Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-032-26472-5_25openalex-snapshot
Human-Induced Pluripotent Stem Cell Models as Predictive Tools to Assess Sex Differences in Cardiovascular Drug Responses
inferred← citeshttps://doi.org/10.1007/978-3-032-29564-4_15openalex-snapshot
Sodium–Glucose Cotransporter-2 Inhibitors for Renoprotection and Cardioprotection in CKD
inferred← citeshttps://doi.org/10.1007/978-3-662-62932-1_12openalex-snapshot
Herz und Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-662-62939-0_12-1openalex-snapshot
Herz und Diabetes
inferred← citeshttps://doi.org/10.1007/978-3-662-69938-6_12openalex-snapshot
Heart and Diabetes
inferred← citeshttps://doi.org/10.1007/978-981-97-7380-0_8openalex-snapshot
Role of ACE Inhibitors and Angiotensin Receptor Blockers in Peripheral Artery Disease
inferred← citeshttps://doi.org/10.1007/978-981-97-7568-2_2openalex-snapshot
SGLT2 Inhibitors and Mechanism of Cardiovascular Benefits in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/978-981-97-7568-2_3openalex-snapshot
SGLT2 Inhibitors for Primary and Secondary Protection from Cardiovascular and Renal Diseases in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/978-981-97-7568-2_4openalex-snapshot
SGLT2 Inhibitors: Emerging Opportunities for the Treatment of Myocardial Infarction
inferred← citeshttps://doi.org/10.1007/978-981-97-7568-2_7openalex-snapshot
A comprehensive Review of Preclinical and Clinical Information on the Cardiovascular Advantages of SGLT2 Inhibitors
inferred← citeshttps://doi.org/10.1007/978-981-97-7568-2_8openalex-snapshot
Exploring the Current Selective Drugs of SGLT2 Inhibitors for the Treatment of Cardiovascular Disease in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1007/s00059-022-05134-6openalex-snapshot
Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard?
inferred← citeshttps://doi.org/10.1007/s00059-024-05286-7openalex-snapshot
Was ist neu im Management der peripheren arteriellen Verschlusskrankheit und der aortalen Erkrankungen?
inferred← citeshttps://doi.org/10.1007/s00108-021-01083-0openalex-snapshot
Gliflozine – in Zukunft Kardioprotektiva?
inferred← citeshttps://doi.org/10.1007/s00125-021-05529-wopenalex-snapshot
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
inferred← citeshttps://doi.org/10.1007/s00125-022-05773-8openalex-snapshot
SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits
inferred← citeshttps://doi.org/10.1007/s00125-022-05787-2openalex-snapshot
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
inferred← citeshttps://doi.org/10.1007/s00125-022-05815-1openalex-snapshot
Ketones: the double-edged sword of SGLT2 inhibitors?
inferred← citeshttps://doi.org/10.1007/s00125-026-06855-7openalex-snapshot
Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
inferred← citeshttps://doi.org/10.1007/s00213-026-07127-3openalex-snapshot
Sotagliflozin pretreatment attenuates acute LPS-induced depression-like behavioral abnormalities and modulates the gut microbiota–immune–brain axis
inferred← citeshttps://doi.org/10.1007/s00228-021-03261-3openalex-snapshot
Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes
inferred← citeshttps://doi.org/10.1007/s00228-024-03631-7openalex-snapshot
The relationship between use of SGLT2is and incidence of respiratory and infectious diseases and site-specific fractures: a meta-analysis based on 32 large RCTs
inferred← citeshttps://doi.org/10.1007/s00392-021-01867-2openalex-snapshot
Timely and individualized heart failure management: need for implementation into the new guidelines
inferred← citeshttps://doi.org/10.1007/s00392-021-01913-zopenalex-snapshot
Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis
inferred← citeshttps://doi.org/10.1007/s00392-022-02148-2openalex-snapshot
Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.1007/s00392-024-02396-4openalex-snapshot
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment
inferred← citeshttps://doi.org/10.1007/s00392-025-02784-4openalex-snapshot
Update on clinical heart failure trials
inferred← citeshttps://doi.org/10.1007/s00392-026-02853-2openalex-snapshot
Characteristics and outcomes of patients with heart failure and reduced left ventricular ejection fraction in relation to sodium-glucose cotransporter-2 inhibitor treatment: real-world data from the multicentre H2-registry
inferred← citeshttps://doi.org/10.1007/s00398-024-00642-5openalex-snapshot
Behandlung von Patienten und Patientinnen mit chronischer Herzinsuffizienz in der perioperativen Phase einer herzchirurgischen Operation
inferred← citeshttps://doi.org/10.1007/s00508-023-02186-4openalex-snapshot
Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023)
inferred← citeshttps://doi.org/10.1007/s00592-021-01757-zopenalex-snapshot
Tandem positive action of SGLT2 inhibitors and ARNI in patients with heart failure
inferred← citeshttps://doi.org/10.1007/s00592-024-02289-yopenalex-snapshot
A comprehensive meta-analysis on the association of SGLT2is and GLP-1RAs with vascular diseases, digestive diseases and fractures
inferred← citeshttps://doi.org/10.1007/s00604-025-07235-5openalex-snapshot
Synergistically enhanced Ni-MOF/CNTs nanocomposite as an electrochemical platform for ultrasensitive determination of sotagliflozin in various matrices, with whiteness and blueness assessments
inferred← citeshttps://doi.org/10.1007/s10557-021-07203-0openalex-snapshot
Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF
inferred← citeshttps://doi.org/10.1007/s10557-021-07243-6openalex-snapshot
SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
inferred← citeshttps://doi.org/10.1007/s10557-021-07249-0openalex-snapshot
Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?
inferred← citeshttps://doi.org/10.1007/s10557-021-07291-yopenalex-snapshot
The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.1007/s10557-021-07301-zopenalex-snapshot
Letter to the Editor Regarding “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”
inferred← citeshttps://doi.org/10.1007/s10557-021-07309-5openalex-snapshot
Response to the Letter on “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”
inferred← citeshttps://doi.org/10.1007/s10557-022-07371-7openalex-snapshot
SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction
showing the first 200 of 1858
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.